According to the American Association for the Study of Liver Diseases (AASLD), the use of GLP-1 receptor agonists, such as Liraglutide, Semaglutide, Dulaglutide, and Exenatide, is recommended for patients with type 2 diabetes mellitus (DM2) and obesity for the treatment of MAFLD to reduce body weight and insulin resistance [50,190,191,192]. The gene discussed is GLP1R; the disease is Insulin resistance.